128 related articles for article (PubMed ID: 35348013)
21. Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy.
Huang Y; Zhang J; Yu Z; Zhang H; Wang Y; Lingel A; Qi W; Gu J; Zhao K; Shultz MD; Wang L; Fu X; Sun Y; Zhang Q; Jiang X; Zhang J; Zhang C; Li L; Zeng J; Feng L; Zhang C; Liu Y; Zhang M; Zhang L; Zhao M; Gao Z; Liu X; Fang D; Guo H; Mi Y; Gabriel T; Dillon MP; Atadja P; Oyang C
J Med Chem; 2017 Mar; 60(6):2215-2226. PubMed ID: 28092155
[TBL] [Abstract][Full Text] [Related]
22. First critical repressive H3K27me3 marks in embryonic stem cells identified using designed protein inhibitor.
Moody JD; Levy S; Mathieu J; Xing Y; Kim W; Dong C; Tempel W; Robitaille AM; Dang LT; Ferreccio A; Detraux D; Sidhu S; Zhu L; Carter L; Xu C; Valensisi C; Wang Y; Hawkins RD; Min J; Moon RT; Orkin SH; Baker D; Ruohola-Baker H
Proc Natl Acad Sci U S A; 2017 Sep; 114(38):10125-10130. PubMed ID: 28864533
[TBL] [Abstract][Full Text] [Related]
23. Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics.
Bao Q; Kumar A; Wu D; Zhou J
Drug Discov Today; 2024 Jun; 29(6):103986. PubMed ID: 38642703
[TBL] [Abstract][Full Text] [Related]
24. Automethylation of PRC2 promotes H3K27 methylation and is impaired in H3K27M pediatric glioma.
Lee CH; Yu JR; Granat J; Saldaña-Meyer R; Andrade J; LeRoy G; Jin Y; Lund P; Stafford JM; Garcia BA; Ueberheide B; Reinberg D
Genes Dev; 2019 Oct; 33(19-20):1428-1440. PubMed ID: 31488577
[TBL] [Abstract][Full Text] [Related]
25. Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.
Huang Y; Sendzik M; Zhang J; Gao Z; Sun Y; Wang L; Gu J; Zhao K; Yu Z; Zhang L; Zhang Q; Blanz J; Chen Z; Dubost V; Fang D; Feng L; Fu X; Kiffe M; Li L; Luo F; Luo X; Mi Y; Mistry P; Pearson D; Piaia A; Scheufler C; Terranova R; Weiss A; Zeng J; Zhang H; Zhang J; Zhao M; Dillon MP; Jeay S; Qi W; Moggs J; Pissot-Soldermann C; Li E; Atadja P; Lingel A; Oyang C
J Med Chem; 2022 Apr; 65(7):5317-5333. PubMed ID: 35352560
[TBL] [Abstract][Full Text] [Related]
26. Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
Zhao Y; Guan YY; Zhao F; Yu T; Zhang SJ; Zhang YZ; Duan YC; Zhou XL
Eur J Med Chem; 2022 Mar; 231():114144. PubMed ID: 35093670
[TBL] [Abstract][Full Text] [Related]
27. Rapid Identification of Novel Allosteric PRC2 Inhibitors.
Read JA; Tart J; Rawlins PB; Gregson C; Jones K; Gao N; Zhu X; Tomlinson R; Code E; Cheung T; Chen H; Kawatkar SP; Bloecher A; Bagal S; O'Donovan DH; Robinson J
ACS Chem Biol; 2019 Oct; 14(10):2134-2140. PubMed ID: 31525019
[TBL] [Abstract][Full Text] [Related]
28. Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer.
Martin MC; Zeng G; Yu J; Schiltz GE
J Med Chem; 2020 Dec; 63(24):15344-15370. PubMed ID: 33283516
[TBL] [Abstract][Full Text] [Related]
29. Distinct Stimulatory Mechanisms Regulate the Catalytic Activity of Polycomb Repressive Complex 2.
Lee CH; Holder M; Grau D; Saldaña-Meyer R; Yu JR; Ganai RA; Zhang J; Wang M; LeRoy G; Dobenecker MW; Reinberg D; Armache KJ
Mol Cell; 2018 May; 70(3):435-448.e5. PubMed ID: 29681498
[TBL] [Abstract][Full Text] [Related]
30. Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).
Dockerill M; Gregson C; O' Donovan DH
Expert Opin Ther Pat; 2021 Feb; 31(2):119-135. PubMed ID: 33103538
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of EED Inhibitors as a Class of PRC2-Targeted Small Molecules for HIV Latency Reversal.
Turner AW; Dronamraju R; Potjewyd F; James KS; Winecoff DK; Kirchherr JL; Archin NM; Browne EP; Strahl BD; Margolis DM; James LI
ACS Infect Dis; 2020 Jul; 6(7):1719-1733. PubMed ID: 32347704
[TBL] [Abstract][Full Text] [Related]
32. The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.
He Y; Selvaraju S; Curtin ML; Jakob CG; Zhu H; Comess KM; Shaw B; The J; Lima-Fernandes E; Szewczyk MM; Cheng D; Klinge KL; Li HQ; Pliushchev M; Algire MA; Maag D; Guo J; Dietrich J; Panchal SC; Petros AM; Sweis RF; Torrent M; Bigelow LJ; Senisterra G; Li F; Kennedy S; Wu Q; Osterling DJ; Lindley DJ; Gao W; Galasinski S; Barsyte-Lovejoy D; Vedadi M; Buchanan FG; Arrowsmith CH; Chiang GG; Sun C; Pappano WN
Nat Chem Biol; 2017 Apr; 13(4):389-395. PubMed ID: 28135237
[TBL] [Abstract][Full Text] [Related]
33. Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domain.
Antonysamy S; Condon B; Druzina Z; Bonanno JB; Gheyi T; Zhang F; MacEwan I; Zhang A; Ashok S; Rodgers L; Russell M; Gately Luz J
PLoS One; 2013; 8(12):e84147. PubMed ID: 24367637
[TBL] [Abstract][Full Text] [Related]
34. Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase.
O' Donovan DH; Gregson C; Packer MJ; Greenwood R; Pike KG; Kawatkar S; Bloecher A; Robinson J; Read J; Code E; Hsu JH; Shen M; Woods H; Barton P; Fillery S; Williamson B; Rawlins PB; Bagal SK
Bioorg Med Chem Lett; 2021 May; 39():127904. PubMed ID: 33684441
[TBL] [Abstract][Full Text] [Related]
35. Convergent evolution of chromatin modification by structurally distinct enzymes: comparative enzymology of histone H3 Lys²⁷ methylation by human polycomb repressive complex 2 and vSET.
Swalm BM; Hallenbeck KK; Majer CR; Jin L; Scott MP; Moyer MP; Copeland RA; Wigle TJ
Biochem J; 2013 Jul; 453(2):241-7. PubMed ID: 23679895
[TBL] [Abstract][Full Text] [Related]
36. A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine.
Catalano R; Rocca R; Juli G; Costa G; Maruca A; Artese A; Caracciolo D; Tagliaferri P; Alcaro S; Tassone P; Amodio N
Eur J Med Chem; 2019 Dec; 183():111715. PubMed ID: 31550663
[TBL] [Abstract][Full Text] [Related]
37. Strategy for "detoxification" of a cancer-derived histone mutant based on mapping its interaction with the methyltransferase PRC2.
Brown ZZ; Müller MM; Jain SU; Allis CD; Lewis PW; Muir TW
J Am Chem Soc; 2014 Oct; 136(39):13498-501. PubMed ID: 25180930
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
[TBL] [Abstract][Full Text] [Related]
39. Inner workings and regulatory inputs that control Polycomb repressive complex 2.
O'Meara MM; Simon JA
Chromosoma; 2012 Jun; 121(3):221-34. PubMed ID: 22349693
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of polycomb repressive complex 2 by targeting EED protects against cisplatin-induced acute kidney injury.
Yu C; Li T; Li J; Cui B; Liu N; Bayliss G; Zhuang S
J Cell Mol Med; 2022 Jul; 26(14):4061-4075. PubMed ID: 35734954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]